anticov.org valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Crawl-delay: | ||
Meta Tags
| Title | Home | ANTICOV |
| Description | AVAREF and ANTICOV: Accelerating regulatory approval for COVID-19 treatments in The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 185.181.163.145 |
| Location | - |
Related Websites
| Site | Rank |
More to Explore
anticov.org Valuation
|
US$1,737
Last updated: 2023-05-20 03:34:05
anticov.org has Semrush global rank of 0. anticov.org has an estimated worth of US$ 1,737, based on its estimated Ads revenue. anticov.org receives approximately 200 unique visitors each day. Its web server is located in -, with IP address 185.181.163.145. According to SiteAdvisor, anticov.org is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,737 |
| Daily Ads Revenue | US$1 |
| Monthly Ads Revenue | US$48 |
| Yearly Ads Revenue | US$577 |
| Daily Unique Visitors | 13 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| anticov.org. | A | 298 | IP: 185.181.163.145 |
| anticov.org. | AAAA | 298 | IPV6: 2001:1600:4:9:f816:3eff:fe0c:fb49 |
| anticov.org. | NS | 3600 | NS Record: ns11.infomaniak.ch. |
| anticov.org. | NS | 3600 | NS Record: ns12.infomaniak.ch. |
HtmlToTextCheckTime:2023-05-20 03:34:05
| Home About Resources Sites Tracker News Press releases Stories In the media Contact Home About Resources Sites Tracker News Press releases Stories In the media Contact Platform trial to find early treatment options for COVID-19 in low-resource settings The ANTICOV clinical trial responds to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in low-resource settings. ANTICOV aims to enrol up to 3,000 participants. The trial was launched in September 2020 in 13 countries by the ANTICOV consortium. The consortium currently includes 27 prominent global research and development organizations, coordinated by the Drugs for Neglected Diseases initiative (DNDi) . One of the largest multi-country trials focusing exclusively on mild and moderate cases of COVID-19, ANTICOV helps address the relative neglect of clinical research during |
HTTP Headers
HTTP/1.1 301 Moved Permanently Date: Mon, 02 Jan 2023 08:40:41 GMT Server: Apache X-Redirect-By: WordPress Upgrade: h2 Connection: Upgrade Location: https://anticov.org/ Content-Type: text/html; charset=UTF-8 HTTP/2 200 date: Mon, 02 Jan 2023 08:40:43 GMT server: Apache strict-transport-security: max-age=16000000 vary: User-Agent,Accept-Encoding last-modified: Fri, 16 Dec 2022 10:43:11 GMT accept-ranges: bytes content-length: 124694 cache-control: max-age=0, no-cache, no-store, must-revalidate pragma: no-cache expires: Mon, 29 Oct 1923 20:30:00 GMT content-type: text/html; charset=UTF-8 |